



## ORIGINAL ARTICLE

# A Study of Intravenous Administration of Vitamin C in the Treatment of Acute Herpetic Pain and Postherpetic Neuralgia

Min Sung Kim, Dong Jin Kim, Chan Ho Na, Bong Seok Shin

Department of Dermatology, Chosun University School of Medicine, Gwangju, Korea

**Background:** Although there are several available management strategies for treatment of both acute pain of herpes zoster (HZ) and postherpetic neuralgia (PHN), it is difficult to treat them adequately. **Objective:** The aim of this study was to evaluate the efficacy of intravenously administered vitamin C on acute pain and its preventive effects on PHN in patients with HZ. **Methods:** Between September 2011 and May 2013 eighty-seven patients who were admitted for HZ were assessed according to age, sex, underlying diseases, duration of pain and skin lesion, dermatomal distribution, and PHN. It was a randomized controlled study, in which 87 patients were randomly allocated into the ascorbic acid group and control group. Each patient received normal saline infusion with or without 5 g of ascorbic acid on days 1, 3, and 5 then answered questionnaires that included side effects and pain severity using visual analogue scale on days 1, 2, 3, 4, and 5. After discharge, the severity of pain was obtained at outpatient clinic or by telephone on weeks 2, 4, 8, and 16. **Results:** There was no differences in severity of pain on patients' age, sex, underlying diseases, duration of pain and skin lesion and dermatomal distribution between two groups ( $p > 0.05$ ). Since 8th week, pain score in ascorbic acid treatment group was significantly lower than control group ( $p$

$< 0.05$ ). The incidence of PHN was significantly lower in the treatment group compared to control group ( $p = 0.014$ ). The changes of overall pain score was significantly different between the two groups ( $p < 0.05$ ). **Conclusion:** Intravenously administered ascorbic acid did not relieve acute HZ pain; but is effective for reducing the incidence of PHN. (Ann Dermatol 28(6) 677~683, 2016)

**-Keywords-**

Ascorbic acid, Herpes zoster, Postherpetic neuralgia

## INTRODUCTION

Herpes zoster (HZ) is an acute skin disease that occurs after primary varicella-zoster virus infection. The virus remains dormant within the dorsal root ganglia and becomes reactivated by the factors that reduce cell-mediated immunity, traveling down the sensory root ganglia to cause acute pain and vesicular eruption<sup>1-3</sup>. HZ can cause pain during the acute phase, as well as various complications and sequelae, including postherpetic neuralgia (PHN), encephalomyelitis, and neural paralysis, even after treatment<sup>3</sup>. Specifically, PHN persists for 1~6 months even after improvement in cutaneous eruption. Its incidence varies with definition, ranging from 8%~15%. It reduces the patient's quality of life because of physical disability and mental disorders<sup>3,4</sup>. Treatment of HZ aims for quick recovery of skin lesions, reduce the intensity and duration of acute pain, and decrease the incidence of complications such as PHN<sup>5,6</sup>. Antiviral drugs, analgesic drugs, lower level laser therapy, and preventive vaccines have been used to alleviate acute pain and PHN; however, treatment of HZ still remains a challenge<sup>2,5,7</sup>.

Received January 4, 2016, Revised February 5, 2016, Accepted for publication February 15, 2016

**Corresponding author:** Bong Seok Shin, Department of Dermatology, Chosun University Hospital, 365 Pilmun-daero, Dong-gu, Gwangju 61453, Korea. Tel: 82-62-220-3130, Fax: 82-62-222-3215, E-mail: derm75@chosun.ac.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Copyright © The Korean Dermatological Association and The Korean Society for Investigative Dermatology

It has been reported that patients with viral infections showed vitamin C deficiency<sup>8</sup>. Vitamin C deficiency has been found to play an important role in the pathogenesis of herpes infection and occurrence of PHN<sup>9,10</sup>. Several studies reported that intravenous (IV) injection of vitamin C is effective in treating acute pain from HZ and PHN<sup>11-13</sup>. However, disputes remain regarding the appropriateness of using vitamin C to treat HZ<sup>14</sup>.

In South Korea, the idea of IV injection of vitamin C to patients with HZ remains incomplete. There are several studies about IV injection of vitamin C twice a day without any side effect. The effect of vitamin C has been reported at a dose of 2.5 g in PHN and at a dose of 7.5 g, 15 g in acute phase<sup>11-13</sup>. Therefore, we designed a study with a dose 5 g of vitamin C injection every two days and we assessed the therapeutic effects of IV injection of it on patients who were diagnosed with HZ and were hospitalized.

## MATERIALS AND METHODS

### Subjects

Of the 128 patients diagnosed with HZ and hospitalized at Department of Dermatology, Chosun University Hospital (Gwangju, Korea) between September 2011 and May 2013, 87 were surveyed. This protocol conformed to the guidelines of the Helsinki Declaration in 1975 and was approved by the institutional review board of Chosun University Hospital, Gwangju, Korea (IRB no. CHOSUN 2015-09-004-003). Patients who received any antiviral medications from a different hospital, who were discharged within 5 days, took analgesic anti-inflammatory drugs to control pain before admission, or were not followed-up after discharge were excluded.

### Study methods

Eighty-seven patients hospitalized for HZ were randomly divided into a vitamin C treatment group and a control group. All patients were intravenously injected with 5 mg/kg of acyclovir for 5 days and orally treated with 100 mg of gabapentin and analgesics (acetaminophen 250 mg/ibuprofen 200 mg/codeine phosphate 10 mg mixture) three times a day to control pain. After discharge, all patients took same dose of analgesics and gabapentin for 1 month. The vitamin C treatment group was provided with a mixture of 100 ml normal saline water and 5 g ascorbic acid on the first, third, and fifth days. The patients in the control group received only 100 ml of normal saline water intravenously. Data on age, sex, underlying diseases, duration and intensity of pain, duration of skin lesions, involved dermatome, PHN, and injection-related complications were collected for all patients.

Visual analogue scale (VAS) score was used on the first, second, third, fourth, and fifth days of admission and second, fourth, eighth, and sixteenth week of follow-up to measure pain intensity, which was assessed using a scale of 10 (most painful) to 0 (no pain), depending on the subjective evaluation of patients. PHN was defined as a pain score >30% of the first pain score even after 4 weeks of developing skin rash<sup>7</sup>, and the occurrence was evaluated 4 weeks after hospitalization.

Age, sex, underlying diseases, time interval of skin lesions (<72 or ≥72 hours) and pain (<5 or ≥5 days) until treatment, involved dermatome, and incidence of PHN were compared between the vitamin C treatment group and the control group. Pain intensity at the given time interval was also compared between the two groups.

### Statistical analysis

Statistical analyses were performed by using IBM SPSS Statistics ver. 22.0 (IBM Co., Armonk, NY, USA). The pain scores of the vitamin C treatment and control groups were measured 9 times with respect to time.

Repeated-measures ANOVA was used to analyze and examine the changes in pain intensity with respect to time. A *p*-value <0.05 was considered statistically significant. Sex, underlying diseases, time interval of skin lesions and pain until treatment, involved dermatome, and incidence of PHN were compared between the two groups by using the Pearson's chi-square test. Age was compared between the two groups by using the t-test.

## RESULTS

### Sex and age distribution

Out of 87 patients, 45 (51.7%) were in the vitamin C treatment group and 42 (48.3%) were in the control group. The mean age of the patients in the vitamin C treatment group was 59.02 years, and the sex distribution was 31 females (68.9%) and 14 males (31.3%). The mean age of the patients in the control group was 59.29 years, and the sex distribution was 22 females (52.4%) and 20 males (47.6%). No statistically significant difference was observed between the two groups (*p*>0.05), and the ratio of women was higher than that of men in both groups (Table 1).

### Involved dermatome

In the vitamin C treatment group, the most common dermatome was the thoracic nerve (21 patients, 46.7%), followed by the trigeminal nerve (9 patients, 20.0%), cervical and sacral nerves (each with 6 patients, 13.3%), and lumbar nerve (3 patients, 6.7%). In the control group, the most common dermatome was also the thoracic nerve (19

**Table 1.** Baseline characteristics of the patients

Characteristic	Vitamin C treatment group (n=45)	Control group (n=42)	<i>p</i> -value
Age (yr)			0.945
Mean $\pm$ SD	59.02 $\pm$ 14.93	59.29 $\pm$ 19.90	
Range (min ~ max)	15 ~ 82	16 ~ 93	
Sex			0.115
Male	14 (31.1)	20 (47.6)	
Female	31 (68.9)	22 (52.4)	
Underlying diseases			0.379
Yes	18 (40.0)	13 (31.0)	
No	27 (60.0)	29 (69.0)	
Onset of pain (d)			0.072
< 5	16 (35.6)	23 (54.8)	
$\geq$ 5	29 (64.4)	19 (45.2)	
Onset of skin lesion (yr)			0.116
< 72	19 (42.2)	11 (26.2)	
$\geq$ 72	26 (57.8)	31 (73.8)	
Incidence of postherpetic neuralgia			0.014
Yes	14 (31.1)	24 (57.1)	
No	31 (68.9)	18 (42.9)	
Distribution of dermatome			0.863
Trigeminal	9 (20.0)	11 (26.2)	
Cervical	6 (13.3)	6 (14.3)	
Thoracic	21 (46.7)	19 (45.2)	
Lumbar	3 (6.7)	1 (2.4)	
Sacral	6 (13.3)	5 (11.9)	

Values are presented as mean  $\pm$  standard deviation, number only, or number (%).

patients, 45.2%), followed by the trigeminal nerve (11 patients, 26.2%), cervical nerve (6 patients, 14.3%), sacral nerve (5 patients, 11.9%), and lumbar nerve (1 patient, 2.4%). Involved dermatome was not statistically significant between the two groups ( $p > 0.05$ ; Table 1).

### Underlying diseases

In the vitamin C treatment group, 18 patients (40.0%) had underlying diseases, whereas 27 patients (60.0%) did not have any underlying diseases. In the control group, 13 patients (31.0%) had underlying diseases, whereas 29 patients (69.0%) did not have any underlying diseases. No statistically significant difference was observed between the two groups ( $p > 0.05$ ; Table 1).

### Time interval of pain and skin lesions until treatment

The period between developing pain and treatment of HZ was set to 5 days. A group of patients who received treatment before the fifth day and another group of patients who received treatment after the fifth day were compared with the patients in the vitamin C treatment and control groups. No statistically significant difference was observed between the two groups ( $p > 0.05$ ). However, the control group had more patients treated within 5 days of develop-

ing pain than the vitamin C treatment group (Table 1). In addition, the period between developing skin lesions and treatment was set to 72 hours, and we compared the vitamin C treatment and control groups in terms of before and after 72 hours. Although no statistically significant difference was observed between the two groups ( $p > 0.05$ ), the vitamin C treatment group had more patients treated within 72 hours (Table 1).

### Incidence of PHN

PHN occurred in 14 patients (31.1%) in the vitamin C treatment group and 24 patients (57.1%) in the control group. The incidence of PHN statistically significantly differed between the two groups ( $p < 0.05$ ; Table 1).


### Changes in pain intensity with time

The pain decreased over time in both groups. In particular, the pain score measured on the eighth week in the vitamin C treatment group significantly differed from that in the control group ( $p = 0.004$ ; Table 2). The pain score was 1.0 for the vitamin C treatment group and lower than 2.01 for the control group. A statistically significant difference was found between the two groups even on the last week ( $p < 0.001$ ). The pain score for the vitamin C treat-

**Table 2.** The changes in the severity of pain between vitamin C treatment group and control group

	Vitamin C treatment group (n=45)	Control group (n=42)	t	p-value
HD1	6.59±2.4	6.21±3.2	0.610	0.544
HD2	4.46±2.2	4.20±2.7	0.478	0.634
HD3	3.42±2.3	3.33±2.5	0.175	0.862
HD4	3.0±2.2	2.86±2.2	0.302	0.763
HD5	2.72±2.3	2.15±1.9	1.271	0.207
Week 2	2.14±1.9	2.68±2.4	-1.146	0.255
Week 4	1.50±1.7	2.16±1.9	-1.643	0.104
Week 8	1.0±1.3	2.01±1.9	-2.932	0.004
Week 16	0.64±0.9	1.98±1.7	-4.474	<0.001

Values are presented as mean±standard deviation. HD: hospital date.



**Fig. 1.** The pain score in the vitamin C treatment group and control group. HD: hospital date, W: week.

ment group (0.64) was lower than that for the control group (1.98) by 1.34 points.

Changes in pain score with respect to time were statistically significant between the vitamin C treatment and control groups (Fig. 1). According to the results of the analysis that compared the effects on the control and vitamin C treatment groups for each time interval, pain score was initially higher in the vitamin C treatment group; but after the 2 weeks of follow up, the pain score for the vitamin C treatment group was lower than the control group. Generally, the pain for the control group was scored low in the early part but increased after the second week of follow up, whereas the pain score in the vitamin C treatment group continuously decreased.

We compared the difference in pain score by age, sex, time interval of pain and skin lesions until treatment, and underlying diseases with respect to time in the vitamin C treatment group (n=45). All of the analyses showed significant differences in pain score with respect to time in general ( $p < 0.001$ ). The patients were categorized by age of 60 years as the standard, and 22 patients (48.9%) were


younger than 60 years and 51.1% were older than 60 years. No significant change in pain score with respect to time were observed between the two age groups ( $p = 0.932$ ; Fig. 2A). However, a significant difference in pain score with respect to time was observed between sexes ( $p = 0.005$ ; Fig. 2B). Pain score decreased in both male and female groups until measured on day 4 of admission, but the pain score for the females slightly increased on the fifth days unlike male. However, after the 2 weeks of follow up, the pain score for the females continuously decreased (from  $2.0 \pm 0.4$  to  $1.2 \pm 0.3$  to  $0.9 \pm 0.2$  to  $0.5 \pm 0.1$ ), exhibiting a lower pain score than that for males (from  $2.4 \pm 0.5$  to  $2.1 \pm 0.5$  to  $1.2 \pm 0.3$  to  $0.9 \pm 0.2$ ). No significant changes in pain score was observed according to time interval of pain and skin lesion until treatment and underlying diseases ( $p = 0.422, 0.161, 0.707$ ; Fig. 2C~E).

### Side effects in the vitamin C treatment group

Of 45 patients from the vitamin C treatment group, 2 (4.4%) had angiodynia at the time of IV vitamin C injection. However, other side effects such as nausea/vomiting, headache, and phlebitis were not observed.

## DISCUSSION

HZ is a skin infection by the reactivation of the varicella zoster virus, which stays dormant after primary infection and develops vesicular skin eruptions unilaterally along the dermatome. PHN persists from several months to several years even after reduction in acute pain and skin rash from HZ, thus largely affecting the patient's quality of life<sup>1-4</sup>. Ninety-six percentage of patients with HZ experience pain, of whom 42% complain of intense pain<sup>4</sup> which is more severe than postoperative or labor pain<sup>15</sup>. The annual prevalence of HZ is 3.2~4.2 cases per 1,000 people in



**Fig. 2.** The pain score change in vitamin C group. (A) In the age <60 and age  $\geq 60$  groups. (B) In the female and male groups. (C) Five days before and after pain. (D) Seventy-two hours within and over skin lesion. (E) In the underlying diseases. Means and standard errors are shown.  $p$ -value was calculated by repeated-measures analysis of variance (RM ANOVA). HD: hospital date, W: week.

the United States. HZ occurs in about 10 per 1,000 people older than 60 years, showing that the incidence of HZ increases with age<sup>6</sup>. In South Korea, it occurs in 10.4 cases per 1,000 people<sup>16</sup>. The annual incidence of HZ in South Korea had increased for the past 5 years<sup>16</sup>, and the burden of disease has also increased due to long-term treatment, compared to that in other countries<sup>17</sup>. The reason is that cell-mediated immunity plays an important role in the reactivation of the varicella zoster virus and the development of HZ, and it decreases with age<sup>15</sup>. Some reported that 10%~30% of the population contracted HZ during

their lifetime<sup>1,4</sup>, and PHN occurred in 18%~33% of them, depending on the age of the patients and evaluation time<sup>11</sup>. Yawn et al.<sup>18</sup> reported that PHN occurred in 18% of patients with HZ and it occurred in 33% of patients older than 79 years, demonstrating that the incidence of PHN increases with age.

PHN persists even with improvement in skin lesions, and it can be defined variously according to the following time points: 1 month, 3 months, 4 months, and 6 months after developing skin rash<sup>3</sup>. Moreover, PHN can also be defined as pain score of more than 3 points and persisting

for 3 months after developing rash<sup>19</sup>. PHN is an intractable peripheral neuropathic pain and can be explained by mechanisms of disinhibition of pain transmission, central sensitization, reactive oxygen species, and neuroinflammation<sup>12,20</sup>. Tricyclic antidepressant is regarded as the primary treatment for PHN, but in the recent years, gabapentin and 5% lidocaine patch are used as primary treatment options<sup>5</sup>. Opioids can be used when patients are resistant to other forms of treatment, and drugs can be chosen according to underlying diseases and patient preference<sup>5</sup>. A recent study reported that HZ vaccinations decreased the burdens of disease by 61%, incidence of HZ by 51%, and the incidence of PHN by 67%. Similarly, Zostavax Efficacy and Safety Trial studies reported that HZ vaccinations significantly decreased the incidence of HZ by 60% in patients aged 50~59 years<sup>2</sup>. In recent studies, oxygen free radicals generated from peripheral inflammation sensitized nociceptors strongly react with noxious stimuli, as well as cause response even to simulation below the threshold. Peripheral sensitization not only causes pain directly but also by inducing central sensitization in the spinal cord<sup>21</sup>. Thus, oxygen free radicals are thought to play a role in the development and maintenance of PHN, and pain is anticipated to be reduced by injecting scavengers of oxygen free radicals<sup>12,20</sup>.

Because vitamin C eliminates excess oxygen free radicals as a scavenger of oxygen free radicals, it is hypothesized to have protective effects on the nerve<sup>12</sup>. Vitamin C is an antioxidant that serves as a cofactor for many enzymes, and plays a role in the synthesis of collagen, neurotransmitter, and numerous neuropeptides. It also has important functions in wound healing, energy metabolism, and nervous system<sup>11</sup>. The high concentration of vitamin C around the immune cells and neurons explains the function of vitamin C<sup>11</sup>. Virus infection generates large amounts of oxygen free radicals, and because vitamin C is used to eliminate oxygen free radicals generated from infection, its concentration can decrease<sup>11,22</sup>. And vitamin C deficiency can be observed in patients with viral infections<sup>8,22</sup>. Vitamin C concentrations were also low in patients with PHN<sup>12,20</sup>. In a recent study, IV injection of high concentrated vitamin C was reported to alleviate acute pain and PHN<sup>12-14,20</sup>. Vitamin C reduces inflammation by production of antiviral cytokine and interferon and detoxification and neutralization of oxygen free radicals, and has direct antiviral effect<sup>22</sup>.

In early investigation, acute phase of HZ was treated using 7.5 g or 15 g dosage of vitamin C, while PHN was treated with 2.5 g of low-dosed vitamin C<sup>11-13</sup>. The results of this study showed that the incidence of PHN statistically significantly was decrease in vitamin C treatment group.

Unlike previous reports, no significant change in acute pain within 4 weeks of hospitalization was observed between the vitamin C treatment and control groups when pain score was compared according to time intervals. However, statistically significant differences were observed after the eighth week and continued thereafter. Consistent with previous studies, we found that low-dose of vitamin C was efficient in the treatment of PHN. As we carried out the study for inpatients treated with IV antiviral therapy, we consider that antiviral treatment may offset the effect of vitamin C. Moreover, changes in overall pain with respect to time showed statistically significant difference between the two groups, and pain was more effectively controlled in the vitamin C treatment group than in the control group. In the vitamin C treatment group, changes in the pain score over time by all variables without sex did not show statistically significant differences. The women showed significant decrease in pain score. Perhaps the more they are sensitive to pain at first, it is considered that they had been better in the treatment reaction.

The adverse effects reported in previous studies were minor such as lethargy/fatigue, local vein irritation, phlebitis, kidney stone, hemolysis and elevated blood glucose<sup>23</sup>. The most common of these side effects were lethargy and fatigue, vein irritation, and nausea and vomiting<sup>23</sup>. When patients have pre-existing renal insufficiency/failure or glucose 6-phosphate dehydrogenase deficiency, a history of oxalate nephrolithiasis or paroxysmal nocturnal hemoglobinuria that is known to predispose to vitamin C toxicity, IV vitamin C should not be administered<sup>23</sup>. However, angiodynia from IV injection due to high vitamin C concentration was found in 2 patients, who did not exhibit angiodynia when they were injected with vitamin C diluted with 250 ml of saline water.

Some limitations of this study were as follows: First, the base vitamin C concentration was not measured; thus, whether the patient had vitamin C deficiency or not was uncertain. Therefore, evaluation of the correlation between vitamin C deficiency and PHN was difficult. Second, pain intensity varied widely between the patients; thus, the objectivity of the VAS was questionable. Third, the vitamin C dosage for treatment of HZ varied<sup>11-13</sup> from 2.5 g, 5 g, 7.5 g, and 15 g, and no standardized intervals for the injections had been established. Fourth, recall bias existed for the patients who did not visit the hospital and were asked to describe their pain over the phone.

IV injection of vitamin C is used widely for fatigue, viral infection, influenza infection, and hepatitis<sup>23</sup>. Furthermore, it is used as a secondary treatment of HZ infection and has demonstrated its effects on acute pain and PHN. But fur-

ther studies on various dosage, interval, and periods are necessary.

In this study, the results did not reflect a significant decrease in acute pain, unlike previous studies, but the treatment was effective in preventing PHN. Also, because of the significant changes in pain over time, we argue that this may be a safe treatment for prevention of PHN and pain from HZ without major side effects.

In conclusion, because acute pain and PHN from HZ significantly affects patient's quality of life, appropriate treatment is important. Various treatments have been introduced to date, but when conventional treatment is unresponsive or management is difficult, IV injection of vitamin C can be used as an effective treatment method to control pain from HZ.

## ACKNOWLEDGMENT

The present study was supported by grants from the Clinical Medicine Research Institute at Chosun University Hospital, 2013.

## REFERENCES

1. Choi WS. Herpes zoster vaccine in Korea. *Clin Exp Vaccine Res* 2013;2:92-96.
2. Song H, Lee J, Lee M, Choi WS, Choi JH, Lee MS, et al. Burden of illness, quality of life, and healthcare utilization among patients with herpes zoster in South Korea: a prospective clinical-epidemiological study. *Int J Infect Dis* 2014;20:23-30.
3. Schmader KE, Oxman MN. Varicella and herpes zoster. In: Goldsmith LA, Katz SI, Gilchrist BA, Paller AS, Leffell DJ, Wolff K, editors. *Fitzpatrick's dermatology in general medicine*. 8th ed. New York: McGraw-Hill, 2012:2383-2401.
4. Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on health-related quality of life. *Clin Infect Dis* 2004;39:342-348.
5. Tyring SK. Management of herpes zoster and postherpetic neuralgia. *J Am Acad Dermatol* 2007;57:S136-S142.
6. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2008;57:1-30; quiz CE2-CE4.
7. Falaki F, Nejat AH, Dalirsani Z. The effect of low-level laser therapy on trigeminal neuralgia: a review of literature. *J Dent Res Dent Clin Dent Prospects* 2014;8:1-5.
8. Jain SK, Pemberton PW, Smith A, McMahon RF, Burrows PC, Aboutwerat A, et al. Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. *J Hepatol* 2002;36:805-811.
9. Terekhina NA, Petrovich IuA, Batueva RA, Sosnin Dlu, Vesna VA. [Lacrimal and salivary antioxidants in viral infection]. *Klin Lab Diagn* 1998;(1):13-15.
10. Chen JY, Chu CC, Lin YS, So EC, Shieh JP, Hu ML. Nutrient deficiencies as a risk factor in Taiwanese patients with postherpetic neuralgia. *Br J Nutr* 2011;106:700-707.
11. Schencking M, Vollbracht C, Weiss G, Lebert J, Biller A, Goyvaerts B, et al. Intravenous vitamin C in the treatment of shingles: results of a multicenter prospective cohort study. *Med Sci Monit* 2012;18:CR215-CR224.
12. Byun SH, Jeon Y. Administration of vitamin C in a patient with Herpes Zoster-a case report-. *Korean J Pain* 2011;24:108-111.
13. Schencking M, Sandholzer H, Frese T. Intravenous administration of vitamin C in the treatment of herpetic neuralgia: two case reports. *Med Sci Monit* 2010;16:CS58-CS61.
14. Peek DF, van Zundert J. The vitamin C controversy. *Clin J Pain* 2010;26:551-552; author reply 552-553.
15. Katz J, Melzack R. Measurement of pain. *Surg Clin North Am* 1999;79:231-252.
16. Kim YJ, Lee CN, Lim CY, Jeon WS, Park YM. Population-based study of the epidemiology of herpes zoster in Korea. *J Korean Med Sci* 2014;29:1706-1710.
17. Rho NK, Park YM, Kang H, Choi GS, Kim BJ, Lee YW, et al. Awareness, knowledge, and vaccine acceptability of Herpes Zoster in Korea: a multicenter survey of 607 patients. *Ann Dermatol* 2015;27:531-538.
18. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. *Mayo Clin Proc* 2007;82:1341-1349.
19. Kawai K, Rampakakis E, Tsai TF, Cheong HJ, Dhitavat J, Covarrubias AO, et al. Predictors of postherpetic neuralgia in patients with herpes zoster: a pooled analysis of prospective cohort studies from North and Latin America and Asia. *Int J Infect Dis* 2015;34:126-131.
20. Chen JY, Chang CY, Feng PH, Chu CC, So EC, Hu ML. Plasma vitamin C is lower in postherpetic neuralgia patients and administration of vitamin C reduces spontaneous pain but not brush-evoked pain. *Clin J Pain* 2009;25:562-569.
21. Chung JM. The role of reactive oxygen species (ROS) in persistent pain. *Mol Interv* 2004;4:248-250.
22. Mikirova N, Hunninghake R. Effect of high dose vitamin C on Epstein-Barr viral infection. *Med Sci Monit* 2014;20:725-732.
23. Padayatty SJ, Sun AY, Chen Q, Espey MG, Drisko J, Levine M. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. *PLoS One* 2010;5:e11414.